Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.62 |
| ▸ | CALCR | P30988 | 4/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | CTSH | P09668 | 1/20 | 0.57 |
| ▸ | GLP1R | P43220 | 7/20 | 0.54 |
| ▸ | GCGR | P47871 | 7/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | GIPR | P48546 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934240 | 0.97 | APLNR (0.61) | APLNRCALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL30567779 | 0.92 | CALCR (0.64) | APLNRCALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL30231481 | 0.90 | CALCR (0.71) | APLNRCALCRGLP1RGCGRGIPR | |
| SCHEMBL30219087 | 0.90 | CALCR (0.71) | APLNRCALCRGLP1RGCGRGIPR | |
| Acetic Acid SCHEMBL30219069 | 0.89 | CALCR (0.70) | APLNRCALCRGLP1RGCGRGIPR | |
| Acetic Acid SCHEMBL30219088 | 0.89 | CALCR (0.70) | APLNRCALCRGLP1RGCGRGIPR | |
| SCHEMBL30219064 | 0.89 | CALCR (0.71) | APLNRCALCRGLP1RGCGRGIPR | |
| SCHEMBL30231506 | 0.89 | CALCR (0.71) | APLNRCALCRGLP1RGCGRGIPR | |
| SCHEMBL29934195 | 0.89 | GLP1R (0.51) | APLNRCALCRGLP1RGCGRKEAP1 | |
| SCHEMBL31255142 | 0.88 | CALCR (0.66) | APLNRCALCRMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12048732-B2 | Methods of treating breast cancer | Blaze Bioscience, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. | 2023-08-17 | — | — | US | disclosed |
| US-20230037660-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | Blaze Bioscience, Inc. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | CHLSN, SLC47A1, CLSPN | APLNR 630/4885CALCR 1387/4885MAPK8 4785/4885 |
| US-20230037660-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | FLT4, FLT1, KDR | APLNR 222/4885CALCR 452/4885MAPK8 3773/4885 |
| US-12048732-B2 | Methods of treating breast cancer | BRCA1, HUNK, MLEC | APLNR 373/4885CALCR 1367/4885MAPK8 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.